Pacific Biosciences of California, Inc. (PACB) in Menlo Park, Calif., provides life scientists with extremely precise sequencing technologies. The company's unique equipment is based on single molecule, real-time Sequencing technology, which provides a complete picture of genomes, transcriptomes, and epigenomes, allowing access to the whole spectrum of genetic diversity in any organism.
The company's shares are down 64.9% in price year-to-date and 22.2% over the past month to close yesterday's trading session at $7.19. In addition, PACB failed to meet consensus sales estimates in its last reported quarter, which further weighed on its stock’s price performance.
